- Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
For: Crohn's DiseaseUnited States · Australia · Austria - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study looks at new ways to treat ulcerative colitis, a condition causing gut inflammation. We're testing a combination of medicines (JNJ-78934804) for people whose current treatments aren't working well. The goal is to see if these new approaches are safe and effective.
For: Colitis, UlcerativeUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter Induction Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
This study is testing a new drug, called Vixarelimab, for adults with moderate to severe ulcerative colitis. It aims to see how well it works to reduce symptoms and improve the gut, as well as checking its safety and how the body handles it.
For: Ulcerative Colitis (UC)Belgium · Germany · France